Alkermes Sinks as FDA Refuses to Approve Depression Drug
Alkermes Plc. ALKS announced that the FDA has issued a Complete Response Letter (“CRL”) related to its new drug application (“NDA”) for ALKS 5461. The NDA sought approval for the candidate as an adjunctive treatment of major depressive disorder (“MDD”) […]